<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">chemicallytech</journal-id><journal-title-group><journal-title xml:lang="en">Fine Chemical Technologies</journal-title><trans-title-group xml:lang="ru"><trans-title>Тонкие химические технологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2410-6593</issn><issn pub-type="epub">2686-7575</issn><publisher><publisher-name>MIREA – Russian Technological University (RTU MIREA).</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.32362/2410-6593-2017-12-1-64-75</article-id><article-id custom-type="elpub" pub-id-type="custom">chemicallytech-75</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CHEMISTRY AND TECHNOLOGY OF MEDICINAL COMPOUNDS AND BIOLOGICALLY ACTIVE SUBSTANCES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ХИМИЯ И ТЕХНОЛОГИЯ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ И БИОЛОГИЧЕСКИ АКТИВНЫХ СОЕДИНЕНИЙ</subject></subj-group></article-categories><title-group><article-title>APPROACHES TO CHORIONIC GONADOTROPIN QUANTITATIVE DETERMINATION IN ANTI-DOPING CONTROL</article-title><trans-title-group xml:lang="ru"><trans-title>КОЛИЧЕСТВЕННОE ОПРЕДЕЛЕНИЕ ХОРИОНИЧЕСКОГО ГОНАДОТРОПИНА В ЦЕЛЯХ АНТИДОПИНГОВОГО КОНТРОЛЯ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зверева</surname><given-names>И. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Zvereva</surname><given-names>I. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник отдела пептидного допинга и анализа крови</p></bio><bio xml:lang="en"><p>Moscow, 105005 Russia</p></bio><email xlink:type="simple">zvereva@dopingtest.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Савельева</surname><given-names>Н. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Savelieva</surname><given-names>N. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>старший научный сотрудник отдела пептидного допинга и анализа крови</p></bio><bio xml:lang="en"><p>Moscow, 105005 Russia</p></bio><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Постников</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Postnikov</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заместитель начальника отдела пептидного допинга и анализа крови</p></bio><bio xml:lang="en"><p>Moscow, 105005 Russia</p></bio><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ефимова</surname><given-names>Ю. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Efimova</surname><given-names>Yu. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доцент</p></bio><bio xml:lang="en"><p>Moscow, 119571 Russia</p></bio><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дикунец</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dikunets</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>директор</p></bio><bio xml:lang="en"><p>Moscow, 105005 Russia</p></bio><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение «Антидопинговый Центр»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Institution “Antidoping Centre”</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский технологический университет (Институт тонких химических технологий)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Technological University (Institute of Fine Chemical Technologies)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>28</day><month>02</month><year>2017</year></pub-date><volume>12</volume><issue>1</issue><fpage>64</fpage><lpage>75</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Zvereva I.O., Savelieva N.B., Postnikov P.V., Efimova Y.A., Dikunets M.A., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Зверева И.О., Савельева Н.Б., Постников П.В., Ефимова Ю.А., Дикунец М.А.</copyright-holder><copyright-holder xml:lang="en">Zvereva I.O., Savelieva N.B., Postnikov P.V., Efimova Y.A., Dikunets M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.finechem-mirea.ru/jour/article/view/75">https://www.finechem-mirea.ru/jour/article/view/75</self-uri><abstract><p>The article presents the results of the first stage of development of a new quantitative method for human chorionic gonadotropin (hCG) determination by means of ultra-high performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) to uncover doping abuse by athletes. The identified tryptic peptides correspond to the most abundant hCG isoforms: the α- and β-subunits, the nicked and β-core fragment of the hormone. Identification and sequencing of specific fragments were performed with the use of nanoLC-MS/MS. A high resolution / high accuracy hybrid mass-spectrometer was applied. Optimization of mass-spectrometric determination of selected specific peptides was accomplished by UPLC-MS/MS. Quantitative evaluation of hCG using specific fragments determination by UPLC-MS/MS allows to detect corresponding hCG isoforms. This significantly increases the method specificity and decreases the probability of false-positive results.</p></abstract><trans-abstract xml:lang="ru"><p>В статье представлены результаты работы, являющейся одним из этапов разработки методики количественного определения хорионического гонадотропина человека (ХГЧ) методом сверхвысокопроизводительной высокоэффективной жидкостной хроматографии в сочетании с тандемной масс-спектрометрией (СВЭЖХ-МС/МС) для выявления случаев его злоупотребления в качестве допинга спортсменами. В ходе работы идентифицированы триптические пептиды, соответствующие наиболее распространенным изоформам ХГЧ: α- и β-субъединицам, расщепленному и коровому фрагменту β-субъединицы гормона. Идентификация и секвенирование специфических фрагментов выполнены методом наноВЭЖХ в сочетании с масс-спектрометрией высокого разрешения с использованием высокоточного и чувствительного масс-спектрометра гибридного типа. Проведена оптимизация масс-спектрометрического определения выбранных специфических пептидов методом СВЭЖХ-МС/МС. Количественное определение ХГЧ по специфическим фрагментам методом СВЭЖХ-МС/МС позволяет однозначно детектировать соответствующие изоформы, что значительно повышает специфичность метода и снижает вероятность получения ложноположительного результата.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хорионический гонадотропин</kwd><kwd>ХГЧ</kwd><kwd>изоформы</kwd><kwd>трипсинолиз</kwd><kwd>сверхпроизводительная ВЭЖХ</kwd><kwd>масс-спектрометрия</kwd><kwd>антидопинговый контроль</kwd></kwd-group><kwd-group xml:lang="en"><kwd>human chorionic gonadotropin</kwd><kwd>hCG</kwd><kwd>isoforms</kwd><kwd>trypsinolysis</kwd><kwd>ultra-HPLC</kwd><kwd>anti-doping control</kwd><kwd>massspectrometry</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kicman A.T., Brooks R.V., Cowan D.A. Human chorionic gonadotrophin and sport // Br. J. Sports Med. 1991. V. 25. № 2. P. 73-80.</mixed-citation><mixed-citation xml:lang="en">Kicman A.T., Brooks R.V., Cowan D.A. Human chorionic gonadotrophin and sport // Br. J. Sports Med. 1991. V. 25. № 2. P. 73–80.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">2014 Anti-Doping Testing Figures Report. [Электронный ресурс] - Режим доступа: https://wada-mainprod. s3.amazonaws.com/wada_2014_anti-doping-testingfigures_full-report_en.pdf (дата обращения 25.08.2016).</mixed-citation><mixed-citation xml:lang="en">2014 Anti-Doping Testing Figures Report. [Электронный ресурс] – Access mode: https://wada-main-prod.s3.amazonaws.com/wada_2014_anti-doping-testingfigures_full-report_en.pdf (date of access  25.08.2016).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">2013 Anti-Doping Testing Figures Report. [Электронный ресурс] - Режим доступа: https:// wada-main-prod.s3.amazonaws.com/wada_2013_antidoping_testing_figures_report_en.pdf (дата обращения 25.08.2016).</mixed-citation><mixed-citation xml:lang="en">2013 Anti-Doping Testing Figures Report. [Electronic resource] – Access mode: https://wadamain-prod.s3.amazonaws.com/wada_2013_antidoping_testing_figures_report_en.pdf (date of access 25.08.2016).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">2012 Anti-Doping Testing Figures Report. [Электронный ресурс] - Режим доступа: https://wada-main-prod.s3.amazonaws.com/resources/files/WADA-2012-Anti-Doping-Testing-Figures-Report-EN.pdf (дата обращения 25.08.2016).</mixed-citation><mixed-citation xml:lang="en">2012 Anti-Doping Testing Figures Report. [Electronic resource] – Access mode: https://wada-mainprod.s3.amazonaws.com/resources/files/WADA-2012-Anti-Doping-Testing-Figures-Report-EN.pdf (date of access 25.08.2016).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Цырлина Е.В., Порошина Т.Е. Хорионический гонадотропин как маркер трофобластической болезни // Практическая онкология. 2008. Т. 9. № 3. С. 150-159.</mixed-citation><mixed-citation xml:lang="en">Tsyrlina E.V., Poroshina T.E. Human chorionic gonadotropin as a marker of trophoblastic diseases // Prakticheskaya onkologiya (Practical Oncology). 2008. V. 9. № 3. P. 150–159. (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bogerd J. Ligand-selective determinants in gonadotropin receptors // Mol. Cell Endocrinol. 2007. V. 2. № 260-262. P. 144-152.</mixed-citation><mixed-citation xml:lang="en">Bogerd J. Ligand-selective determinants in gonadotropin receptors // Mol. Cell Endocrinol. 2007. V. 2. № 260-262. P. 144–152.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">The 2016 Prohibited list. [Электронный ресурс] - Режим доступа: https://www.wada-ama.org/en/resources/science-medicine/prohibited-list (дата обращения 25.08.2016).</mixed-citation><mixed-citation xml:lang="en">The 2016 Prohibited list. [Electronic resource] – Access mode: https://www.wada-ama.org/en/resources/science-medicine/prohibited-list (date of access 25.08.2016).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines reporting &amp; management of urinary human chorionic gonadotrophin (hCG) and luteinizing hormone (LH) findings in male athletes. [Электронный ресурс] - Режим доступа: https://wada-main-prod. s3.amazonaws.com/resources/files/wada-guidelineshcg-lh-findings-v2.0-2015-en.pdf (дата обращения 25.08.2016).</mixed-citation><mixed-citation xml:lang="en">Guidelines reporting &amp; management of urinary human chorionic gonadotrophin (hCG) and luteinizing hormone (LH) findings in male athletes. [Electronic resource] – Access mode: https://wada-main-prod.s3.amazonaws.com/resources/files/wada-guidelineshcg-lh-findings-v2.0-2015-en.pdf (date of access 25.08.2016).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Lund H., Lovsletten K., Paus E., Halvorsen T.G., Reubsaet L. Immuno-MS based targeted proteomics: highly specific, sensitive, and reproducible human chorionic gonadotropin determination for clinical diagnostics and doping analysis // Anal. Chem. 2012. V. 84. № 18. P. 7926-7932.</mixed-citation><mixed-citation xml:lang="en">Lund H., Lovsletten K., Paus E., Halvorsen T.G., Reubsaet L. Immuno-MS based targeted proteomics: highly specific, sensitive, and reproducible human chorionic gonadotropin determination for clinical diagnostics and doping analysis // Anal. Chem. 2012. V. 84. № 18. P. 7926–7932.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Liu C.-L., Bowers L.D. Immunoaffinity trapping of urinary human chorionic gonadotropin and its highperformance liquid chromatographic-mass spectrometric confirmation // J. Chromatogr. B. Biomed. Sci. Appl. 1996. V. 687. P. 213-220.</mixed-citation><mixed-citation xml:lang="en">Liu C.-L., Bowers L.D. Immunoaffinity trapping of urinary human chorionic gonadotropin and its  highperformance liquid chromatographic-mass spectrometric confirmation // J. Chromatogr. B. Biomed. Sci. Appl. 1996. V. 687. P. 213–220.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Gam L.H. Tandem Mass Spectrometry - Applications and Principles / Ed. J. Prasain. Croatia: InTech, 2012. 788 p.</mixed-citation><mixed-citation xml:lang="en">Gam L.H. Tandem Mass Spectrometry – Applications and Principles / Ed. J. Prasain. Croatia: InTech, 2012. 788 p.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gam L.H., Tham S.-Y., Latiff A. Immunoaffinity extraction and tandem mass spectrometric analysis of human chorionic gonadotropin in doping analysis // J. Chromatogr. B. 2003. V. 792. № 2. P. 187-196.</mixed-citation><mixed-citation xml:lang="en">Gam L.H., Tham S.-Y., Latiff A. Immunoaffinity extraction and tandem mass spectrometric analysis of human chorionic gonadotropin in doping analysis // J. Chromatogr. B. 2003. V. 792. № 2. P. 187–196.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Lund H., Torsetnes S.B., Paus E., Nustad K., Reubsaet L., Halvorsen T.G. Exploring the complementary selectivity of immunocapture and MS detection for the differentiation between hCG isoforms in clinically relevant samples // J. Proteome Res. 2009. V. 8. № 11. P. 5241-5252.</mixed-citation><mixed-citation xml:lang="en">Lund H., Torsetnes S.B., Paus E., Nustad K., Reubsaet L., Halvorsen T.G. Exploring the complementary selectivity of immunocapture and MS detection for the differentiation between hCG isoforms in clinically relevant samples // J. Proteome Res. 2009. V. 8. № 11. P. 5241–5252.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Woldemariam G.A., Butch A.W. Immunoextraction-tandem mass spectrometry method for measuring intact human chorionic gonadotropin, free β-subunit, and β-subunit core fragment in urine // Clin. Chem. 2014. V. 60. № 8. P. 1089-1097.</mixed-citation><mixed-citation xml:lang="en">Woldemariam G.A., Butch A.W. Immunoextraction-tandem mass spectrometry method for measuring intact human chorionic gonadotropin, free β-subunit, and β-subunit core fragment in urine // Clin.Chem. 2014. V. 60. № 8. P. 1089–1097.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Stenman U.H., Hotakainen K., Alfthan H. Gonadotropins in doping: pharmacological basis and detection of illicit use // Br. J. Pharmacol. 2008. V. 154. P. 569-583.</mixed-citation><mixed-citation xml:lang="en">Stenman U.H., Hotakainen K., Alfthan H. Gonadotropins in doping: pharmacological basis and detection of illicit use // Br. J. Pharmacol. 2008. V. 154. P. 569–583.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Alfthan H., Haglund C., Dabek J., Stenman U.H. Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women // Clin. Chem. 1992. V. 38. № 10. P. 1981-1987.</mixed-citation><mixed-citation xml:lang="en">Alfthan H., Haglund C., Dabek J., Stenman U.H. Concentrations of human choriogonadotropin, its beta-subunit, and the core fragment of the beta-subunit in serum and urine of men and nonpregnant women // Clin. Chem. 1992. V. 38. № 10. P. 1981–1987.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Grenache D.G., Greene D.N., Dighe A.S., Fantz C.R., Hoefner D., McCudden C., Sokoll L., Wiley C.L., Gronowski A.M. Decreased Human Chorionic Gonadotropin (hCG) Results Due to Increased Concentrations of the Free β Subunit and the β Core Fragment in Quantitative hCG Assays // Clin. Chem. 2010. V. 56. № 12. P. 1839-1844.</mixed-citation><mixed-citation xml:lang="en">Grenache D.G., Greene D.N., Dighe A.S., Fantz C.R., Hoefner D., McCudden C., Sokoll L., Wiley C.L., Gronowski A.M. Falsely Decreased Human Chorionic Gonadotropin (hCG) Results Due to Increased Concentrations of the Free β Subunit and the β Core Fragment in Quantitative hCG Assays // Clin. Chem. 2010. V. 56. № 12. P. 1839–1844.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pan S., Aebersold R., Chen R., Goodlett D.R., McIntosh M.W., Zhang J., Brentnall T.A. Mass spectrometry based targeted protein quantification: methods and applications // J. Proteome Res. 2009. V. 8. № 2. P. 287-297.</mixed-citation><mixed-citation xml:lang="en">Pan S., Aebersold R., Chen R., Goodlett D.R., McIntosh M.W., Zhang J., Brentnall T.A. Mass spectrometry based targeted protein quantification: methods and applications // J. Proteome Res. 2009. V. 8. № 2. P. 287–297.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
